Clinical trials: Hepatitis C, completed
Chronic Hepatitis C
A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers
This is an open-label, two-group, fixed-sequence study to evaluate the effect of ACH-3102 and Simeprevir on AL-335 pharmacokinetics in healthy volunteers.
- Trial name
- NCT02512562
- Testing
- AL-335, ACH-3102, Simeprevir
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Hepatitis B
Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
This was an open-label study that evaluated the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding Hepatitis B surface antigen [HBsAg] and Hepatitis B core antigen [HBcAg]) and…
- Trial name
- NCT02431312
- Testing
- INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 90 people
- Sponsor
- Inovio Pharmaceuticals
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- CITRINE (NCT02803138)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Where
- 18 sites in Israel
- Volunteers
- 256 people
- Sponsor
- AbbVie
Hepatitis C
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with…
- Trial name
- COPE-HCV (NCT00919633)
- Testing
- interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Hypertension, Arthritis
The Health Access and Recovery Peer Program
Individuals with serious mental illnesses (SMI) face high rates of medical comorbidity as well as challenges in managing these conditions.
- Conditions
- Hypertension, Arthritis, Coronary Artery Disease, Hepatitis
- Trial name
- HARP (NCT01725815)
- Testing
- HARP Intervention
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Emory University
Chronic Hepatitis B
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of Morphothiadine Mesilate/Ritonavir combined with Entecavir or Tenofovir Disoproxil Fumarate in healthy subjects
- Trial name
- NCT03662568
- Testing
- GLS4, RTV, ETV
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Acquired Immune Deficiency Syndrome Virus, Hepatitis C
Brief Intervention for Rural Women at High Risk for HIV/HCV
The overall aim of this study is to reduce risk behaviors and increase health and behavioral health service utilization among disadvantaged, drug-using rural women at high risk for HIV and HCV.
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Hepatitis C, Drug Abuse
- Trial name
- WISH (NCT01840722)
- Testing
- MI-based HIV Risk Reduction
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Michele Staton
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- LIFE-C (NCT02615145)
- Volunteers
- 472 people
- Sponsor
- AbbVie
Chronic Hepatitis B
Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus（HBV） vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal…
- Trial name
- NCT00869778
- Testing
- εPA-44
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
Haemophilus Influenzae Type b, Tetanus
Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers
The purpose of the study is to assess the immunogenicity and safety of three formulations of GSK Biologicals' GSK2036874A vaccine compared to Zilbrix™/Hib and Poliorix™ vaccines administered concomitantly, when administered as a…
- Conditions
- Haemophilus Influenzae Type b, Tetanus, Hepatitis B, Whole Cell Pertussis
- Trial name
- NCT01106092
- Testing
- GSK2036874A vaccine, Zilbrix™/Hib vaccine, Poliorix™
- Where
- Philippines
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Exposure to Hepatitis B Virus
Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing…
- Trial name
- NCT01502397
- Where
- Hong Kong
- Volunteers
- 70 people
- Sponsor
- The University of Hong Kong
Hepatitis C, Hepatitis C Relapse
Direct Acting Agents in Hepatitis C Patients
This study is a retrospective study conducted at 36 sites. Planned target patient number is 1000.
- Conditions
- Hepatitis C, Hepatitis C Relapse, Hepatitis C Recurrent
- Trial name
- HEPCTURKEY (NCT03145844)
- Where
- Turkey (Türkiye)
- Volunteers
- 2,700 people
- Sponsor
- Fehmi Tabak
Hepatitis C, Chronic, Chronic Renal Failure
Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir
Sofosbuvir is the base of most treatment regimens for hepatitis C. In patients with renal failure the blood level of one of its metabolites (GS-331007) rises up to 20 folds.
- Trial name
- SD-CRF (NCT03063879)
- Testing
- Sofosbuvir 400 mg and daclatasvir 60 mg
- Where
- Iran
- Volunteers
- 95 people
- Sponsor
- Tehran University of Medical Sciences
Chronic Hepatitis B
Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy
Patients with Chronic Hepatitis B on long term oral antiviral therapy have to continue treatment indefinitely unless they achieve HBeAg seroconversion or HBsAg seroclearance, when therapy can be stopped.
- Trial name
- SWAP (NCT01928511)
- Testing
- peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly, Nucleos(t)ide analogue therapy
- Where
- 4 sites in Singapore
- Volunteers
- 254 people
- Sponsor
- Seng Gee Lim
Diphtheria, Tetanus
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
The purpose of this study is to evaluate the immune response, safety and reactogenicity after receiving combined DTPa-IPV/Hib vaccine when administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age and…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02858440
- Testing
- Infanrix-IPV/Hib
- Where
- 5 sites in Russia
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Liver Cirrhosis
Entecavir for Decompensated HBV Cirrhosis
Entecavir (ETV) and tenofovir (TDF) are the first-line drugs for treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV infection gradually progress to liver cirrhosis.
- Trial name
- NCT03345498
- Testing
- Entecavir
- Where
- India
- Volunteers
- 32 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Pulmonary Artery Hypertension, Chronic Hepatitis c
Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
The purpose of this study is the evaluation of PAH in patients, who are treated with DAA medication for HCV infection.
- Trial name
- NCT04094272
- Testing
- transthoracic doppler-echocardiography (TTE)
- Where
- Switzerland
- Volunteers
- 49 people
- Sponsor
- Kantonsspital Olten
Hepatitis C Infection
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
The purpose of this study is to compare the safety and tolerability of ascending doses of SB 9200 given for up to 14 days to subjects with chronic Hepatitis C infection.
- Trial name
- NCT01803308
- Testing
- SB9200
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 37 people
- Sponsor
- Syneos Health
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia
This is a prospective, multi-center observational study in adult participants chronically infected with hepatitis C virus (HCV) receiving the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir with or without…
- Trial name
- outCome (NCT02851069)
- Where
- 6 sites in Colombia
- Volunteers
- 66 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Children, Only
Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years.
- Trial name
- NCT03764345
- Testing
- Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- National Liver Institute, Egypt